Ignite Creation Date:
2024-05-19 @ 5:34 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06418126
Status:
RECRUITING
Last Update Posted:
2024-05-16
First Post:
2024-04-11
Brief Title:
Prediction of Radiotherapy Efficacy in Patients With Triple-negative Breast Cancer
Sponsor:
Institut de cancérologie Strasbourg Europe
Organization:
Institut de cancérologie Strasbourg Europe
Study Overview
Official Title:
Prediction of Radiotherapy Efficacy in Patients With Triple-negative Breast Cancer TNBC-RT2023
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TNBC-RT2023
Brief Summary:
Recurrence of triple-negative breast cancer TNBC occurs in around 30 of patients within 3 years of treatment For some TNBC patients recurrence occurs on average 26 years after treatment while for others recurrence does not occur early TNBC patients can therefore be divided into two groups those with early recurrence and those who respond well to treatment
At present there are no biomarkers to differentiate these two groups Some studies suggest that radiation-induced inflammatory cytokines may stimulate the development of new metastases Gene expression profiling or protein signatures have not been able to define such biomarkers
The aim of this research protocol is to recruit patients to evaluate if the elevation of the cytokines IL-1β IL-5 and IL-6 in plasma collected during radiotherapy can be used to predict TNBC patients at high risk of recurrence
At present there are no biomarkers to differentiate these two groups Some studies suggest that radiation-induced inflammatory cytokines may stimulate the development of new metastases Gene expression profiling or protein signatures have not been able to define such biomarkers
The aim of this research protocol is to recruit patients to evaluate if the elevation of the cytokines IL-1β IL-5 and IL-6 in plasma collected during radiotherapy can be used to predict TNBC patients at high risk of recurrence
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None